Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine

Alfredo Torres, Anthony E. Gregory, Christopher L. Hatcher, Heather Vinet-Oliphant, Lisa A. Morici, Richard W. Titball, Chad J. Roy

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The Gram-negative Burkholderia mallei is a zoonotic pathogen and the causative agent of glanders disease. Because the bacteria maintain the potential to be used as a biothreat agent, vaccine strategies are required for human glanders prophylaxis. A rhesus macaque (Macaca mulatta) model of pneumonic (inhalational) glanders was established and the protective properties of a nanoparticle glycoconjugate vaccine composed of Burkholderia thailandensis LPS conjugated to FliC was evaluated. An aerosol challenge dose of ~1×104CFU B. mallei produced mortality in 50% of naïve animals (n=2/4), 2-3 days post-exposure. Although survival benefit was not observed by vaccination with a glycoconjugate glanders vaccine (p=0.42), serum LPS-specific IgG titers were significantly higher on day 80 in 3 vaccinated animals who survived compared with 3 vaccinated animals who died. Furthermore, B. mallei was isolated from multiple organs of both non-vaccinated survivors, but not from any organs of 3 vaccinated survivors at 30 days post-challenge. Taken together, this is the first time a candidate vaccine has been evaluated in a non-human primate aerosol model of glanders and represents the initial step for consideration in pre-clinical studies.

Original languageEnglish (US)
Pages (from-to)686-692
Number of pages7
JournalVaccine
Volume33
Issue number5
DOIs
StatePublished - Jan 29 2015

Fingerprint

Glanders
glanders
glycoconjugates
Glycoconjugates
Burkholderia mallei
Gold
Nanoparticles
Primates
Vaccines
vaccines
aerosols
Macaca mulatta
Aerosols
Survivors
Burkholderia thailandensis
Burkholderia
animals
Zoonoses
nanoparticles
clinical trials

Keywords

  • Aerosol
  • Burkholderia mallei
  • Glanders
  • Glycoconjugate
  • Macaques
  • Nanoparticles

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Torres, A., Gregory, A. E., Hatcher, C. L., Vinet-Oliphant, H., Morici, L. A., Titball, R. W., & Roy, C. J. (2015). Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine. Vaccine, 33(5), 686-692. https://doi.org/10.1016/j.vaccine.2014.11.057

Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine. / Torres, Alfredo; Gregory, Anthony E.; Hatcher, Christopher L.; Vinet-Oliphant, Heather; Morici, Lisa A.; Titball, Richard W.; Roy, Chad J.

In: Vaccine, Vol. 33, No. 5, 29.01.2015, p. 686-692.

Research output: Contribution to journalArticle

Torres, A, Gregory, AE, Hatcher, CL, Vinet-Oliphant, H, Morici, LA, Titball, RW & Roy, CJ 2015, 'Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine', Vaccine, vol. 33, no. 5, pp. 686-692. https://doi.org/10.1016/j.vaccine.2014.11.057
Torres, Alfredo ; Gregory, Anthony E. ; Hatcher, Christopher L. ; Vinet-Oliphant, Heather ; Morici, Lisa A. ; Titball, Richard W. ; Roy, Chad J. / Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine. In: Vaccine. 2015 ; Vol. 33, No. 5. pp. 686-692.
@article{df339d3d00854813bcfb06d907a9d2f1,
title = "Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine",
abstract = "The Gram-negative Burkholderia mallei is a zoonotic pathogen and the causative agent of glanders disease. Because the bacteria maintain the potential to be used as a biothreat agent, vaccine strategies are required for human glanders prophylaxis. A rhesus macaque (Macaca mulatta) model of pneumonic (inhalational) glanders was established and the protective properties of a nanoparticle glycoconjugate vaccine composed of Burkholderia thailandensis LPS conjugated to FliC was evaluated. An aerosol challenge dose of ~1×104CFU B. mallei produced mortality in 50{\%} of na{\"i}ve animals (n=2/4), 2-3 days post-exposure. Although survival benefit was not observed by vaccination with a glycoconjugate glanders vaccine (p=0.42), serum LPS-specific IgG titers were significantly higher on day 80 in 3 vaccinated animals who survived compared with 3 vaccinated animals who died. Furthermore, B. mallei was isolated from multiple organs of both non-vaccinated survivors, but not from any organs of 3 vaccinated survivors at 30 days post-challenge. Taken together, this is the first time a candidate vaccine has been evaluated in a non-human primate aerosol model of glanders and represents the initial step for consideration in pre-clinical studies.",
keywords = "Aerosol, Burkholderia mallei, Glanders, Glycoconjugate, Macaques, Nanoparticles",
author = "Alfredo Torres and Gregory, {Anthony E.} and Hatcher, {Christopher L.} and Heather Vinet-Oliphant and Morici, {Lisa A.} and Titball, {Richard W.} and Roy, {Chad J.}",
year = "2015",
month = "1",
day = "29",
doi = "10.1016/j.vaccine.2014.11.057",
language = "English (US)",
volume = "33",
pages = "686--692",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine

AU - Torres, Alfredo

AU - Gregory, Anthony E.

AU - Hatcher, Christopher L.

AU - Vinet-Oliphant, Heather

AU - Morici, Lisa A.

AU - Titball, Richard W.

AU - Roy, Chad J.

PY - 2015/1/29

Y1 - 2015/1/29

N2 - The Gram-negative Burkholderia mallei is a zoonotic pathogen and the causative agent of glanders disease. Because the bacteria maintain the potential to be used as a biothreat agent, vaccine strategies are required for human glanders prophylaxis. A rhesus macaque (Macaca mulatta) model of pneumonic (inhalational) glanders was established and the protective properties of a nanoparticle glycoconjugate vaccine composed of Burkholderia thailandensis LPS conjugated to FliC was evaluated. An aerosol challenge dose of ~1×104CFU B. mallei produced mortality in 50% of naïve animals (n=2/4), 2-3 days post-exposure. Although survival benefit was not observed by vaccination with a glycoconjugate glanders vaccine (p=0.42), serum LPS-specific IgG titers were significantly higher on day 80 in 3 vaccinated animals who survived compared with 3 vaccinated animals who died. Furthermore, B. mallei was isolated from multiple organs of both non-vaccinated survivors, but not from any organs of 3 vaccinated survivors at 30 days post-challenge. Taken together, this is the first time a candidate vaccine has been evaluated in a non-human primate aerosol model of glanders and represents the initial step for consideration in pre-clinical studies.

AB - The Gram-negative Burkholderia mallei is a zoonotic pathogen and the causative agent of glanders disease. Because the bacteria maintain the potential to be used as a biothreat agent, vaccine strategies are required for human glanders prophylaxis. A rhesus macaque (Macaca mulatta) model of pneumonic (inhalational) glanders was established and the protective properties of a nanoparticle glycoconjugate vaccine composed of Burkholderia thailandensis LPS conjugated to FliC was evaluated. An aerosol challenge dose of ~1×104CFU B. mallei produced mortality in 50% of naïve animals (n=2/4), 2-3 days post-exposure. Although survival benefit was not observed by vaccination with a glycoconjugate glanders vaccine (p=0.42), serum LPS-specific IgG titers were significantly higher on day 80 in 3 vaccinated animals who survived compared with 3 vaccinated animals who died. Furthermore, B. mallei was isolated from multiple organs of both non-vaccinated survivors, but not from any organs of 3 vaccinated survivors at 30 days post-challenge. Taken together, this is the first time a candidate vaccine has been evaluated in a non-human primate aerosol model of glanders and represents the initial step for consideration in pre-clinical studies.

KW - Aerosol

KW - Burkholderia mallei

KW - Glanders

KW - Glycoconjugate

KW - Macaques

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=84921293412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921293412&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.11.057

DO - 10.1016/j.vaccine.2014.11.057

M3 - Article

C2 - 25533326

AN - SCOPUS:84921293412

VL - 33

SP - 686

EP - 692

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 5

ER -